Haney Steven A, LaPan Peter, Pan Jing, Zhang Jing
Department of Biological Technologies, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA.
Drug Discov Today. 2006 Oct;11(19-20):889-94. doi: 10.1016/j.drudis.2006.08.015. Epub 2006 Sep 7.
High-content screening (HCS) has been used in late-stage drug discovery for a decade. In the past few years, technological advances have expanded the role of HCS into the early stages of drug discovery, including high-throughput screening and hit-to-lead studies. More recently, computational advances in image analysis and technological advancements in general cell biology have extended the utility of HCS into target validation and basic biological studies, including RNAi screening. The use of HCS in target validation is expanding the work that can be done at this stage, especially the range of targets that can be characterized, and putting it into a more biological context.
高内涵筛选（HCS）已在药物研发后期应用了十年。在过去几年中，技术进步已将HCS的作用扩展到药物研发的早期阶段，包括高通量筛选和从活性分子到先导化合物的研究。最近，图像分析的计算进展和一般细胞生物学的技术进步已将HCS的效用扩展到靶点验证和基础生物学研究，包括RNA干扰筛选。在靶点验证中使用HCS正在扩展这一阶段可以开展的工作，特别是可被表征的靶点范围，并将其置于更具生物学意义的背景中。
